Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects

NCT05252546 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Recurrent / Metastatic Breast Cancer

Interventions

DRUG: pyrotinib tablet
DRUG: Montmorillonite Power
DRUG: Loperamide

Sponsor

Jiangsu HengRui Medicine Co., Ltd.